pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$SMMTSummit Therapeutics Inc.

$SMMT9.9500-5.87%
Miami, FL, USupdated 1d ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
pre_registration: 1
1pre_registration
pre_registration
ivonescimab
Non-Small Cell Lung Cancer

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Oct 19, 2026
earnings
$SMMT9.9500-5.87%
1mo ago
Summit Therapeutics Inc. earnings
Summit Therapeutics Inc.
→
view all catalysts →

Active trials

  • phase3A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinomarecruitingn=800
  • phase3Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1recruitingn=780
  • phase3Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancerrecruitingn=600
  • phase3Phase III Study of AK112 for NSCLC Patientsactive not recruitingn=420
  • phase3Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patientsrecruitingn=1,600
  • phase3Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjectsterminatedn=2
🐶 Hiring Signal
No open roles indexed yet — view Summit Therapeutics Inc. jobs →

News

  • This week in charts: Biotech investors’ China bets are already paying off
    This year, companies built around medicines from China have sped toward acquisitions or IPOs. Meanwhile, Summit is no longer the Wall Street darling it was in 2024.
    biopharma_dive · 2d ago
  • FDA’s search for a new leader, and China’s largest drugmakers
    This week on "The Readout LOUD" podcast: the FDA is again searching for a new leader and a closely tracked lung cancer drug suffers an agency rejection.
    stat · 2d ago
  • STAT+: FDA discloses reasons for rejecting Summit drug
    The FDA published its complete response letter to Summit Therapeutics explaining why it rejected the biotech's closely watched lung cancer drug:
    stat · 4d ago
  • FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK
    The FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts.
    biopharma_dive · 4d ago
  • Summit’s rejection letter reveals FDA’s deeper concerns about trial design, safety
    Summit Therapeutics was warned twice by the FDA that the Phase 3 trial used to support the application for ivonescimab did not include patients that accurately represented the American population.
    biospace · 4d ago
  • Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight
    The FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech hist…
    biospace · 4d ago
  • 5 acquisitions that forced Big Pharmas to co-parent
    Acquiring a biotech with an existing Big Pharma partner can impose financial and strategic constraints around data sharing and milestone and royalty payments—but it is “rarely a deal-breaker,” acco…
    biospace · 4d ago
  • FDA letter rejecting Summit cancer drug cites ‘modest’ benefit in data compared with toxicity risk
    The FDA signaled new interest in the safety of Summit Therapeutics and Akeso’s cancer drug ivonescimab, saying that it turned down the treatment’s use in a form of lung cancer in part ...
    endpoints · 4d ago
  • FDA’s complete response letter for Summit’s ivonescimab cites China-heavy data beyond survival miss
    The FDA’s rejection of Summit Therapeutics’ closely watched PD-1xVEGF bispecific ivonescimab extends beyond its previously reported failure to show a statistically significant overall survival bene…
    fiercebiotech · 5d ago
  • Summit shares fall as FDA rejects closely watched PD-1/VEGF drug
    The FDA refused to overlook ivonescimab’s failure to initially extend survival in a form of lung cancer, setting back Summit’s first chance to win a U.S. approval.
    biopharma_dive · 6d ago
view all news mentions →
identifiers
ticker
$SMMT
SEC CIK
0001599298
country
US
source
sec_tickers
top tags
NSCLC1Oncology1
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 36m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?